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Runt-related transcription factor 2 (RUNX2/Cbfa1) is the main regulatory
gene controlling skeletal development and morphogenesis in vertebrates. It
is located on chromosome 6p21 and has two functional isoforms (type I and
type II) under control of two alternate promoters (P1 and P2). Mutations
within RUNX2 are linked to Cleidocranial dysplasia syndrome (CCD) in
humans. CCD is an autosomal skeletal disorder characterized by several
features such as delayed closure of fontanels, dental abnormalities and
hypoplastic clavicles. Here, we summarize recent knowledge about RUNX2
function, mutations and their phenotypic consequences in patients.
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RUNX2 (CBFA1/AML3/PEBP2αA) is one of three
members of RUNX family of Runt-related transcription
factors (RUNX1-3). RUNX1 participates in hematopoi-
etic stem cell differentiation (1) and mutations in this
gene result in myeloid leukemia (2). RUNX2 is necessary
for osteoblast differentiation, skeletal morphogenesis (3,
4), and mutations in this gene lead to Cleidocranial dys-
plasia (CCD) in humans (OMIM #119600). RUNX3 acts
as a tumor suppressor gene and was found to be linked to
gastric cancer (5). This review will summarize the recent
progress in studies of various mutations in RUNX2 and
their phenotypic consequences in CCD.
RUNX2 structure
The human and murine RUNX2 genes are localized on
chromosome 6p21 (6) and 17 (7), respectively. Human
RUNX2 gene comprises a region of 223 kb in size
(Chr6:45328317-45551082) (6) and consists of eight
exons. Nevertheless, several authors have numbered
exons differently depending on the use of alternate
promoters and/or alternative splicing yielding 12 tran-
script variants encoding protein isoforms of RUNX2. For
instance, Terry et al. (8) identified two alternate promo-
tors and reported differential utilization of 3′ terminal
exons in mouse and human. They also distinguished nine
alternatively spliced exons among which exist three vari-
ants of exon 5 (5, 5.1, 5.2) and two alternatives of exon 6
(6, 6.1). Moreover, Makita et al. (9) distinguished three
alternatively spliced isoforms that arises from omission
of exon 5 and/or exon 7 (figures (8, 9)).
RUNX2 presents two in-frame ATG codons, both
of which can serve as potential translation start sites.
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Two promoters drive expression of both isoforms with
different spatiotemporal pattern which suggests special-
ized functions of each (10). The gene expression from the
proximal promoter (P2) generates type I RUNX2 mRNA
differing at the 5′ end from the type II RUNX2 mRNA
being under control of P1 distal promoter. P1 promoter is
termed the ‘bone-related’ because of driving expression
of the isoform widely associated with bones (11–16).
The translation start codon for the type I RUNX2 is sit-
uated within exon 2 and encodes 507-amino acid protein
starting with the MRIPV N-terminal sequence (MRIPV
isoform; UniProt: Q13950-2) (17). The alternative start
codon of type II localizes within exon 1, thus protein
begins with the MASNS sequence and is 521-amino
acid long (MASNS isoform; UniProt: Q13950-1) (18)
(Fig. 1).
In spite of abundance of information, the consistent
exon numbering has not been established. Specifically,
the exon 1 (9, 12, 14, 19, 20) is termed by some
authors ‘exon 0’ (21–24). Nonetheless, MASNS isoform
is indicated as ‘canonical’ for osteogenesis (13). More
importantly, recently NCBI annotation team removed the
507-aa MRIPV annotation (isoform c; NM_004348.3)
due to insufficient support for existence of that isoform.
Thus, two main remaining isoforms are 521-aa MASNS
(isoform 1 or a; NM_001024630.3; NP_001019801.3)
and 485-aa MRIPV without seventh exon (isoform 4
or d; NM_001278478.1; NP_001265407) (Fig. 1). Fur-
thermore, NCBI and ENSEMBL nomenclature differs
in transcript lengths and there is no clear distinction
between type I (MRIPV) and type II (MASNS) RUNX2.
RUNX2 is a multidomain protein which in this review
will be described in N to C terminal order. The deletion
analysis identified the first 19 amino acid fragment as
the first activation domain. Next, QA domain com-
posed of glutamine–alanine repeats (23 Q and 17 A
repeats) is located within N-terminus with a transacti-
vation activity as well. Additionally, it has been shown
that this domain can prevent heterodimerization of type
II RUNX2 with CBFβ (core-binding factor subunit beta)
(25). This transcriptional partner of RUNX proteins
improves its DNA-binding affinity by promoting struc-
tural changes that reveal RUNX2-DNA interaction sur-
face (26). CBFβ also protects and stabilizes RUNX pro-
teins against proteolytic degradation (27, 28). CBFβ does
not bind directly to DNA but heterodimerizes with Runt
homologous domain (RHD). All members of RUNX
family (RUNX1-3) are characterized by the presence
of that highly conserved motif, homologous to pair-rule
gene runt involved in body segmentation of Drosophila
melanogaster (6). RHD consists of 128 amino acids
and is responsible for DNA binding (17) to a DNA
motif TGXGGTX (X is pyrimidine) (29). A 9-amino
acid sequence (PRRHRQKLD) following RHD acts as
nuclear localization signal (NLS). This domain is related
to the NLS of c-Myc, and is conserved within all RUNX
proteins (25).
The NLS domain is followed by the pro-
line/serine/threonine rich region (PST) necessary for
transcriptional activation of target genes (third transacti-
vation domain) and containing the phosphorylation sites
recognized by Akt kinase (30, 31). Also ERK/MAPK
and PKA kinases phosphorylate RUNX2 protein but
in different regions [for review (32)]. Next domain is
the nuclear matrix targeting sequence (NMTS). This 38
amino acids motif determines RUNX2 subnuclear local-
ization and displays binding affinity to other proteins
like histone deacetylase (30, 33). At the very C-terminus
Fig. 1. Schematic representation of RUNX2. (a): RUNX2 gene spans 222.71 kb and is under the control of two promoters: P1 and P2. Coding sequence
are marked as black boxes and length of coding sequences is in block; green boxes indicate 5′UTR and 3′UTR, and UTR length is in green; grey
line shows introns. (b) Representation of two types of RUNX2: type I and type II starting with MRIPV or MASNS, respectively. QA, polyglutamine
and polyalanine domain, RHD, runt homologous domain; NLS, nuclear localization signal; PST, proline/serine/threonine rich region; NMTS, nuclear
matrix targeting signal; VWRPY, carboxyterminal pentapetide.
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is present the VWRPY pentapeptide sequence which
is recognized as a repression domain. This motif is
also conserved among all runt proteins and interacts
with transcriptional corepressor TLE2 (transducing-like
enhancer of split 2) (25, 34) (Fig. 1).
Biological function of RUNX2
Bones are formed through one of two ossification pro-
cesses: (i) intramembranous based on direct conver-
sion and differentiation of mesenchymal progenitors into
osteoblasts occurring in parts of the craniofacial skeleton
as well as the clavicle (35) or (ii) endochondral ossifi-
cation. In this process, mesenchymal cells differentiate
into chondrocytes, which undergo hypertrophy leading
among others to the secretion of vascular endothelial
growth factor (VEGF) that attracts blood vessels, and
permits the formation of bone marrow cavity concomi-
tant with osteoblast differentiation.
RUNX2 is essential for differentiation of osteoblast
during both intramembranous and endochondral ossifi-
cation. Hypertrophy of chondrocytes is positively regu-
lated byRUNX2which activates the expression of typeX
collagen (36). Other factors such as SOX9, IHH (Indian
hedgehog), PTHRP (parathyroid hormone-related pro-
tein) and BMPs (bone morphogenetic proteins) are also
responsible for tight regulation of endochondral bone
formation (37–40). The initial osteoblast differentiation
is triggered through IHH induced by RUNX2 (41–43).
RUNX2 activates the IHH promoter and thus stimulates
IHH expression in prehypertrophic chondrocytes, which
regulates chondrocyte proliferation and maturation
through IHH/PTHRP loop (Fig. 2) (44, 45). Addition-
ally, IHH induces expression of RUNX2 in neighboring
perichondrium but full commitment to osteoblasts
requires Osterix (Osx) transcription factor for both types
of ossification (46). Also RUNX2, as a transcription
factor involved in bone formation, upregulates the
expression of bone matrix genes including collagen I,
osteocalcin, bone sialoprotein and osteopontin.
Normal bone development requires precise spatiotem-
poral regulation of RUNX2 expression and several
factors have been associated with this process, and it has
been a subject of a recent review (47). Some factors such
as Msh homeobox 2 (Msx2), twist or promyelocytic
leukemia zinc-finger protein (PLZF), Osx participate
in the induction of RUNX2 expression. Others like
sex-determining region Y-box 9 (Sox9) acts as a repres-
sor due to interaction with runt domain. Additionally,
STAT family transcription factor (Stat1) inhibits nuclear
localization of RUNX2. It is worth mentioning that
extending recent knowledge about complex regulation
of bone formation by transcription factors is essential for
further studies in field of TF-targeted gene therapy (48).
RUNX2 type I and type II regulate expression of
bone-related genes, however it has been suggested that
they might have different functions in skeletogenesis
(10). Type I, is expressed in T cells, osteoblasts and
chondrocytes (49) and contributes to the intramembra-
nous bone development (50). The expression of Type II
increases during osteoblast differentiation (14, 51), and it
Fig. 2. Regulation of osteoblast and chondrocyte maturation by
RUNX2. IHH, Indian hedgehog; PTHrP, parathyroid hormone-related
protein; OSX, osterix; green lines indicate induction, red, inhibition and
dashed line shows the expression of IHH.
has been shown to be responsible for endochondral bone
formation (10). Furthermore, it was reported that these
isoforms vary in their dependence on the Cbfβ cofactor
(52). Moreover, RUNX2 is also responsible for regulat-
ing expression of genes that, when deregulated, cause
craniosynostosis like NEL-like 1 (NELL1). It also plays
a role in hormonal regulation of bone formation by tak-
ing part in glucocorticoid signaling pathway necessary
for normal osteogenesis (48).
Besides its osteogenic function, RUNX2 has also been
linked to breast and prostate cancer and specifically
with more aggressive phenotype of these diseases (31,
53–55). Additionally, high expression of RUNX2 is
observed in cancers that have high tendency to metas-
tasize to skeleton (56).
Animal models to study Runx2 function
Targeted inactivation of the gene in mouse results in
the phenotype similar to CCD in humans. Specifically,
mice were displaying skeletal, CCD-like, abnormali-
ties and had decreased body weight. In heterozygous
mice (RUNX2+/−) formation of the tooth primodorium
was delayed but otherwise normal. Since mice present
only one dentition, development of supernumerary teeth
does not occur like it does in humans with CCD (18).
Homozygous (RUNX2−/−) mice died soon after birth,
and during postmortal examination, failure in bone ossi-
fication was detected (48).
Number of experiments have been performed to estab-
lish the role of RUNX2 mutations in CCD pathology.
Lou et al. (57) generated a hypomorphic RUNX2 mutant
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allele (RUNX2neo7) where only part of the transcript
was processed to full length. This model allowed them
to determine the minimal expression level of RUNX2
required for normal skeletal development. Specifi-
cally, PGK (cGMP-dependent protein kinase)-driven
neomycine resistance cassette (PGKneo) was inserted
into intron 7 interfering with splicing and reducing
the expression of wild-type mRNA. The insertion of
PGKneo into exon 7 resulted in alternative splicing
between exon 7 of RUNX2 and neo cassette. This led to
expression of mutant protein lacking C-terminus (thus
still including NMTS and a repression domain) (57). It is
not excluded that observed phenotype can be a dominant
negative activity resulting in the production of partial
protein. Nonetheless, their findings demonstrate that less
than 70% of wild-type RUNX2 level resulted in CCD
phenotype, whereas mice expressing RUNX2 at higher
level showed no skeletal abnormalities. Interestingly, it
was also reported that RUNX2 overexpression can also
cause dysplasia. Experiment resulted in mice suffering
from osteopenia along with bone fractures (58).
Bone unrelated function of RUNX2 has been described
in zebrafish (Danio rerio) where the gene is an essen-
tial determinant for ventral zygotic genes. Importantly,
two additional orthologues of mammalian gene called
RUNX2a and RUNX2b sharing sequence and structure
homology have been identified in zebrafish but with
divergent expression patterns explaining the retention of
duplicate genes through evolution (59). Further studies
in zebrafish revealed that RUNX2b appears to be the
only known regulator of Vent family of transcription
factors (60). Members of this family, VOX, VENT and
VED, play a role as repressors in dorsoventral axis estab-
lishment (61). Depletion of RUNX2b results in loss of
expression of VOX, VENT and VED and consequently
in embryo dorsalization. Silencing experiments showed
that RUNX2b2 regulation of VENT transcription factors
is direct, by interacting with promoter. Additionally, res-
cue experiments in zebrafish using murine RUNX2 type
2 shown that it can substitute for zebrafish orthologues,
suggesting that RUNX2 role in axis formation could be
evolutionarily conserved (60).
Recently, it has been shown that Runx2 regulates fate
of epithelial cells of mammary glands during breast
cancer development. Deletion of Runx2 during preg-
nancy in mice decreased differentiation by disrupting
population of alveolar progenitor cells while exogenous
overexpression of Runx2 in mammary epithelial cells
impaired milk production. These findings suggest that
decreased amount of endogenous Runx2 is required for
full differentiation. Additionally, it was observed that
overexpression of RUNX2 led to transition changes in
normal mammary epithelial cells while its deletion in
developing breast cancer inhibited cancerous cellular
phenotype (62).
Runx2 in CCD
CCD was initially described as cleidocranial dysostosis
since it was believed to affect only membranous-derived
bones. Further clinical studies have shown that the
disorder affected skeleton in general, not only skull
and clavicles, so it should be considered as dysplasia
rather than dysostosis (63). Spectrum of phenotypes is
wide, ranging from mildly affected patients with dental
and clavicles anomalies only to individuals with severe
defects in skeletal development. Intriguingly, these phe-
notypic variations occur evenwithin one family (64). The
most common features of CCD are delayed closure of
fontanels and cranial sutures, brachycephaly, depressed
nasal bridge, supernumerary teeth, delayed eruption of
permanent teeth, Wormian bones and hypoplasia of clav-
icles (65). Since it was suggested that RUNX2 regulates
not only skeleton development but also the expression
of mesenchymal tissue, controlling differentiation o den-
tal epithelium, it could partially explain dental abnor-
malities. Mutations associated with severe dental abnor-
malities (supernumerary teeth, eruption failure) affect
Runt-domain. In contrast, mild dental problems are cor-
relatedwithmutations outside the Runt-domain (66–68).
Mutations in human RUNX2
Majority of RUNX2 mutations in individuals suffer-
ing from classic CCD occur in the runt domain and
the most common DNA disruptions are missense muta-
tions that prevent RUNX2 binding to DNA or non-
sense mutations that result in biosynthesis of truncated
protein. While missense mutations are uniquely found
within runt-domain region, nonsense and frame-shift
types were described throughout the gene (22, 63, 66,
69–80) (Fig. 3, Table 1).
A screening analysis within a group of Japanese
patients was carried out to investigate the link between
a mutation and its phenotypic manifestation (67). It
described 15 heterozygous mutations among 24 families
and 1 polymorphism.Most of discovered mutations were
missense and all of them located within runt-domain
which confirmed results reported previously (81).
Besides six missense, seven nonsense and frame-shift
mutations, two exon-skipping mutations between third
exon and intron were also identified. One of them,
IVS3+3delAAGT, occurred within splice-donor signal
leading to in-frame skipping of the complete third
exon. This resulted in decreased functionality of donor
site where GT motif was followed by segment rich in
pyrimidine (AAGTACTC) (67). Second exon-skipping
mutation, cIVS3+2T>C, was present at the same donor
site. It is worth mentioning that different study also
described skipping of exon 5 although in this case
runt domain and NLS remained intact (81). Extensive
genetic analysis of patient groups with CCD led to dis-
covery of several polymorphisms. D170, synonymous
mutation, caused by c510T>C was identified within
second exon on one allele in one patient. Mother of
the patients was a homozygous carrier of this mutation
as well (67). In the second case, polymorphism – A80
(c240A>G) – was found on one allele of patient and
the mother. The causative silent transition was located
within Q/A region (65). Besides the missense mutations
(Table 1), several other mutations have been reported
such as a mutation in runt-domain, T200A that does
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Fig. 3. Schematic representation of mutation types within RUNX2 gene. QA, polyglutamine and polyalanine domain; RHD, runt homologous
domain; NLS, nuclear localization signal; PST, proline/serine/threonine rich region; NMTS, nuclear matrix targeting signal VWRPY-carboxyterminal
pentapetide.
not affect binding to DNA and is correlated with mild
CCD phenotype manifested only by delayed eruption
of permanent teeth (81). Electrophoretic mobility shift
assay (EMSA) of wild-type and mutant protein revealed
that T200A mutation did not affect neither the binding
to OSE2 nor transactivation activity. In vivo effect of
T200A mutation remains thus unknown. One could
speculate that the mutation may be hypomorphic but in
vitro studies are not sufficiently sensitive. Alternatively,
the mutation may have neomorphic nature and affect
different functions of runt domain (81).
Besides point mutations, intragenic microdeletions
have been also reported for RUNX2 and linked to CCD.
A family has been identified having intragenic deletion
covering region between exons 2 and 6, including runt
domain and NLS. Mutation was detected within three
generations of this family and all patients presented
short stature and small hands (82, 83). Another case of
microdeletion involved not only RUNX2 but also other
gene, VEGF, located 4.6Mb away. Phenotype reflected
the defects for both genes: characteristic features of CCD
and degenerated pattering of pharyngeal arch-derived
arteries, characteristic for VEGF, were observed (84).
Besides microdeletion, the genomic region containing
RUNX2 has also been microduplicated. Recently, large
duplication downstream of RUNX2 has been discovered
in CCDpatients who suggested that regulatory sequences
of RUNX2 may be disrupted in this case. Family did
not participate in further analysis, so segregation analysis
and additional gene diagnostics of a possible pathogenic
effect of the duplicated region were not carried out (85).
Moreover, a case of family where three children,
one of them a half-brother, presented all features of
classic CCD phenotype while the mother examina-
tion showed no abnormalities (86). Sequencing analy-
sis revealed 864insC mutation within exon 6 in affected
family members and a single nucleotide polymorphism
IVS6+46G>A in the same exon in themother. High reso-
lution melting analysis was performed in order to test for
maternal mosaicism. Results, showing different melting
profiles in each patient, pointed to a possibility of addi-
tional sequence variation in mother. Further, subcloning
and resequencing identified 864insC mutation in several
clones isolated from blood or buccal swab samples. It
was found in cis to IVS6+46G allele therefore confirm-
ing low-level mosaicism in mother (86).
Recently, a novel duplication 181_189dupGCGGGC
GGCT was reported resulting in expansion of polyala-
nine residues within Q/A domain and, in consequence,
in CCD phenotype. Further experiments confirmed that
increasing number of alanine residues has a signifi-
cant impact on RUNX2 transcriptional activity. Expan-
sion by 3 Ala did not impair the normal activity of
RUNX2 while 10 Ala expansion significantly decreased
it. The Ala expansion caused rapid intracellular aggre-
gation of RUNX2 resulting in the protein exclusion
from the nuclei (87). Recently, the plausible connec-
tion between the number of alanine repeats within QA
domain and the absence of clavicles in patients with
CCD has been revealed. The analysis of polyalaninie
tracts in warm blooded mammals (including human)
revealed that species having 17 or 18 alanine tracts
have clavicles, while the absence of repeats or its
increased number is associated with the reduction or
lack of clavicles (88). Polyalanine repeats however are
not the only ones linked with CCD phenotype since
a case of polyglutamine tract insertion was reported
(213_214insCAGCAGCAGCAG), also in Q/A domain,
resulting in reduced transactivation of RUNX2 (89).
Genotype–phenotype correlation
It has been notoriously difficult to establish direct
genotype–phenotype correlation for RUNX2 because
of very variable phenotypic penetrance of the muta-
tions (4). Most mutations occurring within runt-domain
result in a classical CCD phenotype. There are however
some intriguing exceptions like heterozygous T200A
mutation. It was found in father who suffered only
from dental abnormalities, but his two children showed
all the features of CCD (81). Another example of an
unusual genotype–phenotype correlation is an inser-
tion mutation localized at the beginning of the tran-
script, between two translational start sites, 90insC. It
was described to be associated with mild CCD pheno-
type and abnormal dentition (81). Another study inves-
tigated phenotype–genotype correlation in a large group
of patients. Patients from one group hadmutations within
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Table 1. Precise location of mutations within RUNX2 genea
Mutation type
Exon number Nonsense Missense Frame-shift
1 (1–19 aa)
2 (20–141 aa) c.190 C>T [Q64X]
c.193 C>T [Q65X]]
c.196 C>T [Q66X]
c.273T>A [L93X]
c. 276_277ins17
[L93X]
c.334G>T [E112X]
c.383 C>A [S128X]
c.389G>A [W130X]
c.396 C>A [C132X]
c.338T>G [L113R]
c.354 C>T [S118R]
c.362T>G [F121C]
c.366_367delGTinsTC
[C123R]
c.391 C>G [R131G]
c.391 C>T [ R131C]
c.391 C>A [R131S]
c.407T>C [L136P]
c.90_91insC
c.92_93insCGGT
c.134_135insGTCC
c.136delC
c.207_208ins13
c.230-276del
c.274delC
c.282delG
c.329delC
3 (142–194 aa) c.481-482delGA
[D161X]
c.484G>T [E162X]
c.535 C>T [R179X]
c.577 C>T [R193X]
c.467T>A [V156D]
c.475G>C [G159R]
c.506G>C [R169P]
c.523 A>G [M175V]
c.524T>A [M175L]
c.524T>G [M175R]
c.526 C>T [R176W]
c.548T>C [F183S]
c.560T>C [F187S]
c.568C>T [R190W]
c.569G>A [R190Q]
c.572G>A [S191N]
c.578G>A [R193Q]
c.453delT
c.469insA
c.476delG
c.495delT
c.522insA
c.532delC
c.549delC
c.553_554delCT
4 (194–229 aa) c.590T>C [F197S]
c.599C>T [T200I]
c.602T>A [I201K]
c.612A>T [K204N]
c.614C>G [T205R]
c.617 C>T [T206I]
c.627 A>T [Q209H]
c.631G>C [A211P]
c.632G>A [R211Q]
c. 635- 638delCCTA [T212I]
c.652 A>C [L218Q]
c.652 A>G [L218E]
c.662T>G [V221G]
c.667G>A [G223R]
c.673 C>T [R225W]
c.674G>A [R225Q]
c.674G>T [R225L]
c.682 A>G [R228G]
c.592delA
c.624_625insCC
c.635_638delCCTA
c.636delC
c.644delG
5 (229–287 aa) c.694 C>T [Q232X]
c.793 C>T [Q266X]
c.838 C>T [Q280X]
c.817G>A [D273N]
c.859G>A [D287N]
c.718_721del
c.722delT
c.824delG
c.831delT
6 (287–341 aa) c.896 C>T [P299L] c.873_874delCA
c.879_885del
c.884delC
c.887delC
c.915delC
c.977delG
7 (341–363 aa) c.1056G>A [W352X] c.1085 C>T [A362V] c.1043 C>T (splice region variant)
8 (363–521 aa) c.1096G>T [E366X]
c.1171 C>T [R391X]
c.1182T>A [Y394X]
c.1254 C>A [Y418X]
c.1259 C>A [T420N]
c.1259 C>T [T420I]
c.1531G>A [G511S]
1565G>C [X522S] (stop lost)
c.1111_1129del19
c.1119delC
c.1127_1128insT
c.1153_1154delAG
c.1157delG
c.1169delC
c.1205delC
c.1205_1206insC
c.1250_1251delAC
c.1335_1336delCT
c.1379_1380insC
c.1385insG
aThe table contains the data as available in public databases on April 2016.
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runt-domain. Individuals from the second group had
runt-domain unaffected while did have all the features
of CCD. This suggests that phenotype may be caused
by mutation in a regulatory region on RUNX2 or in
other gene interacting with RUNX2. Besides the range
of CCD phenotypes present in these patients, most com-
mon difference was the height score, significantly lower
in group with impaired runt-domain. Findings suggested
that growth of the skeleton deteriorates when one allele
activity is lower by around 50% and it progressively
worsens with further loss of gene activity (67).
There is also a weak genotype–phenotype corre-
lation in case of dental aspect of CCD phenotypes,
especially with respect to teeth development (90).
Among several hypotheses trying to explain phenotype
diversity, one suggests that intramembranous bone
formation may require more RUNX2 in comparison
to endochondral-mediated skeletal bones development
(67). Additionally, recent report demonstrates that there
are more dental-related phenotypes correlated with
CCD describing a sporadic case of 14 supernumer-
ary teeth in 20-year old individual. Patient was found
with, previously unreported, fused primary teeth due
to c.578G>A (R193Q) mutation (68). There are many
similarities between osteo- and odontogenesis. This,
together with the role that osteoblasts play in the forma-
tion of mandible and maxilla, explains the severity of
craniofacial phenotypes in CCD patients (91).
In summary, RUNX2 is a master regulatory gene
for skeletal development and morphogenesis. Muta-
tions within the gene or its regulatory regions are
commonly found in CCD patients. Further studies
are however necessary to establish in more detail the
genotype–phenotype correlation (Table 2) (63, 74, 86,
87, 89, 90, 92) and to fully understand mechanism of
underlying pathogenesis of CCD.
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